Nov 29, 2006 Press Release for Alnylam

Alnylam to Webcast its R&D Day on Tuesday, December 5, 2006

Nov 29, 2006

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 29, 2006--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that its R&D Day presentation will be webcast live on the "Investors" section of the company's website at www.alnylam.com.

Alnylam's management, scientists, and other invited speakers will review the company's research and development programs. The presentations will be delivered on Tuesday, December 5, 2006 from approximately 8:30 a.m. to 11:45 a.m. ET from the Sofitel New York in New York City. A replay of the presentation will be posted on the Alnylam website approximately three hours after the event, and will be archived for 30 days.

About Alnylam
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus (RSV) infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec. The company, founded in 2002, maintains global headquarters in Cambridge, Massachusetts, and has an additional operating unit in Kulmbach, Germany. Alnylam is honored to be the "emerging/mid-cap" company recipient of the 2006 James D. Watson Helix Award, the biotechnology industry's award for outstanding achievement. For more information, visit www.alnylam.com.

SOURCE: Alnylam Pharmaceuticals, Inc.

CONTACT:
Investors:
Cynthia Clayton,
Alnylam Pharmaceuticals, Inc.
1+617-551-8207
or
Media:
Kathryn Morris,
1+845-635-9828